ePT--the Electronic Newsletter of Pharmaceutical Technology, May 5, 2011 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

ePT--the Electronic Newsletter of Pharmaceutical Technology, May 5, 2011
News
FDA to Study Online Drug Marketing
By Angie Drakulich
FDA is collecting public comments on a series of studies that the agency plans to conduct on online direct-to-consumer promotion of prescription drug products, according to an announcement in the Federal Register.
Teva Snatches Cephalon from Valeant
By Rich Whitworth
Israel-based Teva Industries seals deal to acquire Cephalon for $6.8 billion.
PhRMA Urges Congress to Reauthorize Legislation for Pediatric Drugs
By Patricia Van Arnum
PhRMA Urges Congress to Reauthorize Legislation for Pediatric Drugs.
Excipient-Certification Standards Presented for Comment
By Erik Greb
The IPEC is soliciting public comment about a draft plan for the independent certification of manufacturers and suppliers of pharmaceutical excipients.
Federal Appeals Court Lifts Ban on Funding for Embryonic Stem Cell Research
By Amy Ritter
A federal appeals court has lifted a ban on federal funding for embryonic stem cell research.
Week of May 5, 2011: Company and People Notes: Velesco partners with Vindonwestech; NeurogesX announces retirement of CEO Anthony DiTonno; and More.
Velesco partners with Vindonwestech; NeurogesX announces retirement of CEO Anthony DiTonno; and More.
Regulatory Roundup: FDA Calling on Industry to Provide Feedback on Existing Regulations
FDA Calling on Industry to Provide Feedback on Existing Regulations.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
9%
Provide treatment for patients globally.
9%
All of the above.
41%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Click here